Dan Pollyea, MD, MS

Articles by Dan Pollyea, MD, MS

Dr. Pollyea on the Role of Maintenance Therapy in AML

April 14th 2022

Dan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

Latest Updated Articles

Dr. Pollyea on the Role of Maintenance Therapy in AML
April 14th 2022

Trending on OncLive

FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC

Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy

Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC

QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML

A Randomized Phase III Study Evaluating Izalontamab Brengitecan (Iza-bren) Versus Physician’s Choice of Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)